- Home
- VALN vs NAGE Comparison
VALN vs NAGE Comparison
Compare VALN & NAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALN
- NAGE
- Stock Information
- Founded
- VALN 2012
- NAGE 1999
- Country
- VALN France
- NAGE United States
- Employees
- VALN N/A
- NAGE N/A
- Industry
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- NAGE Medicinal Chemicals and Botanical Products
- Sector
- VALN Health Care
- NAGE Health Care
- Exchange
- VALN Nasdaq
- NAGE Nasdaq
- Market Cap
- VALN 820.0M
- NAGE 766.4M
- IPO Year
- VALN 2021
- NAGE N/A
- Fundamental
- Price
- VALN $9.43
- NAGE $6.93
- Analyst Decision
- VALN Strong Buy
- NAGE Strong Buy
- Analyst Count
- VALN 4
- NAGE 3
- Target Price
- VALN $15.75
- NAGE $16.33
- AVG Volume (30 Days)
- VALN 21.9K
- NAGE 1.0M
- Earning Date
- VALN 11-20-2025
- NAGE 11-04-2025
- Dividend Yield
- VALN N/A
- NAGE N/A
- EPS Growth
- VALN N/A
- NAGE 1093.81
- EPS
- VALN N/A
- NAGE 0.23
- Revenue
- VALN $211,089,992.00
- NAGE $124,709,000.00
- Revenue This Year
- VALN $6.86
- NAGE $29.51
- Revenue Next Year
- VALN $11.85
- NAGE $20.55
- P/E Ratio
- VALN N/A
- NAGE $29.33
- Revenue Growth
- VALN 13.48
- NAGE 36.04
- 52 Week Low
- VALN $3.62
- NAGE $5.16
- 52 Week High
- VALN $12.25
- NAGE $14.69
- Technical
- Relative Strength Index (RSI)
- VALN 56.66
- NAGE 44.01
- Support Level
- VALN $8.53
- NAGE $6.79
- Resistance Level
- VALN $8.92
- NAGE $7.11
- Average True Range (ATR)
- VALN 0.33
- NAGE 0.29
- MACD
- VALN 0.07
- NAGE 0.05
- Stochastic Oscillator
- VALN 89.57
- NAGE 49.25
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
About NAGE Niagen Bioscience Inc. Common Stock
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.